Health Care Equipment

LBP Medicine

LBP Medicine released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 79.55 M, actual EPS CNY -0.02

LBP Medicine FY2026 Q1 Earning Release on April 29 After-Market (BJT)

LBP Medicine to Release FY2025 Earnings Report on April 29, 2026 Pre-Market (BJT)

LBP Medicine released FY2025 Q4 earnings on February 27 Pre-Market (BJT), actual revenue CNY 91.53 M, actual EPS CNY -0.3388

LBP Medicine released FY2025 Annual Earnings on February 27 Pre-Market (BJT), with actual revenue of CNY 344.45 M and EPS of CNY -0.5

LBP Medicine released FY2025 9 Months earnings on October 27 After-Market (BJT), actual revenue CNY 252.92 M, actual EPS CNY -0.1118

LBP Medicine released FY2025 Q3 earnings on October 27 After-Market (BJT), actual revenue CNY 93.52 M, actual EPS CNY 0.0225

LBP Medicine FY2025 Q3 Earnings Release Scheduled for October 28 After-Market BJT

LBP Medicine released FY2025 Q2 earnings on August 21 Pre-Market (BJT), actual revenue CNY 86.85 M, actual EPS CNY -0.0143

LBP Medicine released FY2025 Semi-Annual Earnings on August 21 Pre-Market (BJT), actual revenue CNY 159.4 M, actual EPS CNY -0.13

LBPMedicin to Release FY2025 Semi-Annual Earnings on August 22, 2025 (BJT)

Anbi Ping Obtains HPV Nucleic Acid Test Kit Registration

Anbi Ping Obtains Medical Device Registration for Cervical Sample Detection

Anbi Ping Obtains EU CE Certification for 14 Products

Multiple Shareholders of Anbipei Plan to Transfer 1.8715 Million Shares via Quotation Inquiry

ABPlife Aims to Capture Top Hospitals, Digitalization Revenue Surpasses Ten Million

Anbi Ping's Net Profit Declined Sharply in Q1 2025

LBPMedicin released FY2025 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 72.54 M, actual EPS CNY -0.12

LBPMedicin FY2025 Q1 Earnings Release Scheduled for April 30 After-Market BJT

Anbi Ping Reports Revenue and Net Profit Declines in 2024

688393

301042

With the disclosure of the fourth quarter report for 2025, the latest holdings of foreign public funds such as BlackRock, Fidelity, Luminor, Allianz, Schroders, and Wellington have come to light. Data shows that these funds have made significant investments in the Chinese technology sector and achieved remarkable results in the market rise of 2025

Wallstreetcn

Raysharp

Deepening in the Chinese technology sector, the latest holdings of foreign public funds have been released

On the evening of August 21, LBPMedicin disclosed its 2025 semi-annual report, achieving operating revenue of 159 million yuan in the first half of the year, a year-on-year decrease of 30.11%; net profit attributable to the parent company was -12.4985 million yuan, turning from profit to loss year-on-year; basic earnings per share were -0.13 yuan

Zhitong

LBPMedicin: Loss of 12.4985 million yuan in the first half of the year

According to the announcement from LBPMedicin, due to the funding needs of shareholders, Nanjing Qianjing intends to reduce its holdings of the company's shares by no more than 1.6773 million shares (including this number) through centralized bidding and block trading, which does not exceed 1.79% of the company's current total share capital

LBPMedicin: Nanjing Qianjing plans to reduce its holdings by no more than 1.79% of its shares

LBPMedicin announced that five of its products have obtained EU CE certification, allowing them to be sold in the EU and European Economic Area markets, and facilitating entry into other international markets. The certified products include a film dyeing integrated machine, a fully automatic sealing machine, and several companion consumables

LBPMedicin's multiple products have obtained EU CE certification

According to the Zhitong Finance APP, LBPMedicin announced that the company recently received the "Medical Device Registration Certificate (In Vitro Diagnostic Reagents)" issued by the National Medical Products Administration, with the product name: Human Papillomavirus Nucleic Acid Detection Kit (Real-time Fluorescent PCR Method)

LBPMedicin obtained a medical device registration certificate

300244

300253

000710

Beijing has introduced the "Artificial Intelligence + Pharmaceutical Health" Innovation Development Action Plan, aimed at accelerating the cultivation of new quality productivity. Since 2025, several AI medical concept stocks have performed outstandingly, with Berry Genomics, LBPMedicin, and Xinlitai increasing by 73.37%, 69.83%, and 55.34% respectively; Winning Health, Elon Technology, Hongbo Pharmaceutical, WuXi AppTec, and Dian Diagnostics have all seen increases of over 30%

Dian Diagnostics

Winning Health

Berry Genomics

Major AI medical policies released, 19 stocks worth paying attention to

LBPMedicin announced that 14 of its products have obtained EU CE certification, allowing sales in the EU and European Economic Area (EEA) markets, and facilitating entry into other international markets. This certification will broaden the overseas application scenarios of the products. The company has also obtained market access qualifications in several countries and plans to accelerate its international layout

LBPMedicin's some products have obtained EU CE certification

LBPMedicin announced a shareholder inquiry transfer plan, with shareholders including Zhuji Gaotejia and others intending to transfer a total of 2% of the company's shares, totaling 1.8715 million shares. The shareholders participating in this inquiry transfer include Zhuji Gaotejia, Chongqing Gaotejia, Hangzhou Gaotejia, and Hangzhou Ruihong

LBPMedicin: Shareholders including Zhuji Gaotejia plan to inquire about the transfer of a total of 2% of the company's shares

LBPMedicin released its 2024 annual performance, with operating revenue of 471 million yuan, a year-on-year decrease of 5.33%; net profit attributable to the parent company of 21.2913 million yuan, a year-on-year decrease of 46.85%; net profit excluding non-recurring gains and losses of 14.2538 million yuan, a year-on-year decrease of 59.64%; basic earnings per share of 0.23 yuan/share. The company plans to distribute a cash dividend of 1.00 yuan (tax included) for every 10 shares

LBPMedicin released its 2024 annual performance, with a net profit attributable to the parent company of 21.2913 million yuan, a year-on-year decrease of 46.85%

36Kr learned that the three major A-share indices opened higher collectively, with the Shanghai Composite Index opening up 0.02%, the Shenzhen Component Index up 0.18%, and the ChiNext Index up 0.26%; reports indicate that Huawei is forming a medical and health team, leading to a strong opening for medical stocks, with Chenguang Medical rising over 14% and LBPMedicin rising over 11%; the metals and engineering machinery sectors led the gains, with Luoping Zinc & Electricity rising over 9% and Sany Heavy Industry rising over 1%; the diversified finance, commercial services, and cultural media sectors saw the largest declines, with AVIC Capital falling over 3%, Gan Consult falling over 2%, and GuiGuang Network falling over 1%

36Kr

GZCBN

GANSU ENGINEERING CONSULTING

Sany

Huawei

LPXD

The three major A-share indices opened higher collectively, with healthcare stocks strengthening at the opening

LBP Medicine(688393.SH)